ShangPharma opens new plant to support Eli Lilly

Published: 10-Jan-2012
Research & Development Finance

Also signs a multi-year extension of its contract with the US firm


ShangPharma Corporation, a China-based pharmaceutical and biotechnology research and development outsourcing company, has opened a new facility to meet the growing needs of one of its largest customers, Eli Lilly. ShangPharma has also signed a multi-year extension of its contract with the US pharmaceutical firm.

ShangPharma’s newly opened plant adds 110,000ft2 of laboratory and office space to its overall capacity, and is fully dedicated to supporting Lilly's ongoing and future projects.

‘Renewing our agreement to serve as a key support partner for Lilly's discovery services is a clear indication that international pharmaceutical companies appreciate the high quality of ShangPharma's team and the excellence of our r&d capability,’ said Michael Xin Hui, founder and chief executive of ShangPharma.

  • Companies:
  • Eli Lilly
  • ShangPharma
See more

You may also like

Drug Delivery

Eli Lilly to leverage ViaNautis Bio's nanovesicle technology for genetic medicine development

Read more
ViaNautis' polyNaut nanovesicles can deliver genetic materials to specific tissues or cell types, allowing for more accurate therapeutic targeting

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  5. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Drug Delivery

Eli Lilly to leverage ViaNautis Bio's nanovesicle technology for genetic medicine development

ViaNautis' polyNaut nanovesicles can deliver genetic materials to specific tissues or cell types, allowing for more accurate therapeutic targeting
Research & Development

Eli Lilly to buy bowel biopharma company Morphic

The USD $3.2bn deal will boost Eli Lilly’s offerings for patients with inflammatory bowel disease, including a number of Phase II therapeutic candidates
Research & Development

Redwire’s Lab-in-a-Box aims to leverage the ISS National Lab to improve drug manufacturing
Regulatory

NICE recommends Lilly’s mirikizumab for the treatment of Ulcerative Colitis

Eli Lilly has received the "go ahead" from NICE, the organisation that has recommended its mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis
Manufacturing

Lilly set to acquire Versanis Bio to "improve patient outcomes in cardiometabolic diseases"

Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash
Research & Development

Lilly and ProQR to expand RNA editing collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilising ProQR’s Axiomer technology
Research & Development

Bachem signs 7-year agreement with Eli Lilly to accelerate oligonucleotide production

Bachem, the Swiss pharmaceutical company, has partnered with Eli Lilly, an American pharmaceutical firm, to further advance the development of oligonucleotide-based drug substances
Subscribe now